Title Participants Abstract "Assessment of health state in patients with tinnitus: A comparison of the EQ-5D and HUI mark III" "Rilana Cima, Johan Vlaeyen" "OBJECTIVES: Expressing the outcomes of treatment in quality-adjusted life years is increasingly important as a tool to aid decision makers concerning the allocation of scarce resources within the health care sector. A quality-adjusted life year is a measure of life expectancy that is weighted by health-related quality of life. These weights are referred to as utility scores and are usually measured by multiattribute utility measures. Several studies found that different utility measures provide different estimates of the same person's level of utility. The aim of this study was to investigate which of two widely used utility measures, the EQ-5D and the HUI mark III, is preferred in a tinnitus population. METHODS: Baseline and follow-up data on EQ-5D and HUI mark III of 429 patients of a randomized controlled clinical trial, investigating cost-effectiveness of usual care versus specialized care of tinnitus, were included. Agreement, discriminative power, and responsiveness of the health state description and the utility scores were examined. RESULTS: Corresponding dimensions of the EQ-5D and HUI mark III showed large correlations; although ceiling effects were more frequently observed in the EQ-5D. Mean utility scores for EQ-5D (0.77; SD 0.22) and HUI mark III (0.64; SD 0.28) were significantly different (Wilcoxon signed ranks test, p < 0.001), and agreement was low to moderate (intraclass correlation coefficient = 0.53). Both health state description and utility scores of both measures discriminated between different severity groups. These groups were based on baseline scores of the Tinnitus Questionnaire. The HUI mark III had a higher ability than the EQ-5D to detect improved patients from randomly selected pairs of improved and unimproved patients. CONCLUSION: This study shows that different utility measures lead to different health state descriptions and utility scores among tinnitus patients. However, both measures are capable of discriminating between clinically different groups. The HUI mark III is more responsive than the EQ-5D, and therefore preferred in a tinnitus population." """Rendez à chaque culte ce qui lui est propre""" "Adriaan Overbeeke" "A three-arm phase III randomized trial of FOLFOX-4 vs. FOLFOX-4 plus bevacizumab vs. XELOX plus bevacizumab in the adjuvant treatment of patients with stage III or high-risk stage II colon cancer: results of the interim safety analysis of the AVANT trial" "Eric Van Cutsem" "Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer" "Giacomo Bregni, Caroline Vandeputte, Andrea Pretta, Chiara Senti, Elena Trevisi, Elena Acedo Reina, Pashalina Kehagias, Gabriel Liberale, Luigi Moretti, Maria Antonietta Bali, Pieter Demetter, Patrick Flamen, Javier Carrasco, Lionel D'Hondt, Karen Geboes, Yeter Gokburun, Marc Peeters, Marc Van den Eynde, Jean-Luc Van Laethem, Philippe Vergauwe, Camille Anastasia Chapot, Marc Buyse, Amelie Deleporte, Alain Hendlisz, Francesco Sclafani" "NEUROCOGNITIVE FUNCTIONING IN EORTC BRAIN TUMOR GROUP RANDOMIZED PHASE II TAVAREC TRIAL (EORTC 26091, NCT01164189) ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB in 1p/19q INTACT RECURRENT GRADE II AND III GLIOMAS" "Martin Klein, Jaap C Reijneveld, Ahmed Idbaih, Walter Taal, Paul Clement, Filip de Vos, Antje Wick, Paul Mulholland, Martin JB Taphoorn, Joanne Lewis, Michael Weller, Tina Verschuere, Vassilis Golfinopoulos, Thierry Gorlia, Martin van den Bent" "CLINICAL RESULTS OF THE EORTC RANDOMIZED PHASE II TAVAREC TRIAL ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB IN 1ST RECURRENCE OF GRADE II OR III GLIOMA WITHOUT 1p/19q CO-DELETION" "Martin van den Bent, Paul Clement, Filip Vos, Michael Platten, Paul Mulholland, Martin Taphoorn, Joanne Lewis, Thierry Gorlia, Vassilis Golfinopoulos, Ahmed Idbaih, Olivier Chinot" "FIRST RESULTS OF THE RANDOMIZED PHASE II TAVAREC TRIAL ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB IN 1P/19Q INTACT 1ST RECURRENCE GRADE II AND III GLIOMA" "Paul Clement" "Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II and III surveys in eight European countries" "K Kotseva, D Wood, Gui De Backer, Dirk De Bacquer, K Pyörälä, U Keil" "Background The first and second EUROASPIRE surveys showed high rates of modifiable cardiovascular risk factors in patients with coronary heart disease. The third EUROASPIRE survey was done in 2006-07 in 22 countries to see whether preventive cardiology had improved and if the joint European Societies' recommendations on cardiovascular disease prevention are being followed in clinical practice. Methods EUROASPIRE I, II, and III were designed as cross-sectional studies and included the same selected geographical areas and hospitals in the Czech Republic, Finland, France, Germany, Hungary, Italy, the Netherlands, and Slovenia. Consecutive patients (men and women = 30 kg/m(2)) increased from 25.0% in EUROASPIRE I, to 32.6% in 11, and 38.0% in III (p=0.0006). The proportion of patients with raised blood pressure (>= 140/90 mm Hg in patients without diabetes or >= 130/80 mm Hg in patients with diabetes) was similar (58.1% in EUROASPIRE 1, 58.3% in II, and 60.9% in III; p=0.49), whereas the proportion with raised total cholesterol (>= 4.5 mmol/L) decreased, from 94.5% in EUROASPIRE I to 76.7% in II, and 46.2% in III (p" "Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial" "Paul Clement" "BACKGROUND: Bevacizumab is frequently used in the treatment of recurrent WHO grade II and III glioma, but without supporting evidence from randomised trials. Therefore, we assessed the use of bevacizumab in patients with first recurrence of grade II or III glioma who did not have 1p/19q co-deletion. METHODS: The TAVAREC trial was a randomised, open-label phase 2 trial done at 32 centres across Europe in patients with locally diagnosed grade II or III glioma without 1p/19q co-deletion, with a first and contrast-enhancing recurrence after initial radiotherapy or chemotherapy, or both. Previous chemotherapy must have been stopped at least 6 months before enrolment and radiotherapy must have been stopped at least 3 months before enrolment. Random group assignment was done electronically through the European Organisation for Research and Treatment of Cancer web-based system, stratified by a minimisation procedure using institution, initial histology (WHO grade II vs III), WHO performance status (0 or 1 vs 2), and previous treatment (radiotherapy, chemotherapy, or both). Patients were assigned to receive either temozolomide (150-200 mg/m2, orally) monotherapy on days 1-5 every 4 weeks for a maximum of 12 cycles, or the same temozolomide regimen in combination with bevacizumab (10 mg/kg, intravenously) every 2 weeks until progression. The primary endpoint was overall survival at 12 months in the per-protocol population. Safety analyses were done in all patients who started their allocated treatment. The study is registered at EudraCT (2009-017422-39) and ClinicalTrials.gov (NCT01164189), and is complete. FINDINGS: Between Feb 8, 2011, and July 31, 2015, 155 patients were enrolled and randomly assigned to receive either monotherapy (n=77) or combination therapy (n=78). Overall survival in the per-protocol population at 12 months was achieved by 44 (61% [80% CI 53-69]) of 72 patients in the temozolomide group and 38 (55% [47-69]) of 69 in the combination group. The most frequent toxicity was haematological: 17 (23%) of 75 patients in the monotherapy group and 25 (33%) of 76 in the combination group developed grade 3 or 4 haematological toxicity. Other than haematological toxicities, the most common adverse events were nervous system disorders (59 [79%] of 75 patients in the monotherapy group vs 65 [86%] of 76 in the combination group), fatigue (53 [70%] vs 61 [80%]), and nausea (39 [52%] vs 43 [56%]). Infections were more frequently reported in the combination group (29 [38%] of 76 patients) than in the monotherapy group (17 [23%] of 75). One treatment-related death was reported in the combination group (infection after intratumoral haemorrhage during a treatment-related grade 4 thrombocytopenia). INTERPRETATION: We found no evidence of improved overall survival with bevacizumab and temozolomide combination treatment versus temozolomide monotherapy. The findings from this study provide no support for further phase 3 studies on the role of bevacizumab in this disease. FUNDING: Roche Pharmaceuticals." "Clinical reality of coronary prevention in Europe: a comparison of EUROASPIRE I, II and III surveys" "K Kotseva, C Jennings, Dirk De Bacquer, Gui De Backer, D Wood"